Elevated Prevalence of Obesity, Metabolic Syndrome, and Cardiovascular Risk Factors in Bipolar Disorder

References

• Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: Follow-up over 34–38 years. J Affect Dis-ord. 2002;68:167–181.
   Google Scholar
• Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord. 1994;31:91–96.
   Google Scholar
• Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord. 1987;13:287–292.
   Google Scholar
• Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, Simonsen C, Vaskinn A, Birkeland KI, Friis S, Sundet K, Andreassen OA. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: A comparative study. J Clin Psychiatry. 2007;68:917–923.
   Google Scholar
• Raphael T, Parsons JP. Blood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatry. 1921;5:681–709.
   Google Scholar
• Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156:1417–1420.
   Google Scholar
• Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, Conigliaro J, Haas GL. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6:368–373.
   Google Scholar
• Johannessen L, Strudsholm U, Foldager L, Munk-Jorgensen P. Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia. J Affect Disord. 2006;95:13–17.
   Google Scholar
• Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, Kessler RC. Association between obesity and psychiatric disorders in the U.S. adult population. Arch Gen Psychiatry. 2006;63:824–830.
   Google Scholar
• Shah A, Shen N, El-Mallakh RS. Weight gain occurs after onset of bipolar illness in overweight bipolar patients. Ann Clin Psychiatry. 2006;18:239–241.
   Google Scholar
• McElroy SL, Frye MA, Suppes T, Dhavale D, Keck Jr PE, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63: 207–213.
   Google Scholar
• Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7:424–430.
   Google Scholar
• Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, Oral ET, Atagun I. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98:247–252.
   Google Scholar
• Cardenas J, Frye MA, Marusak SL, Levander EM, Chirichigno JW, Lewis S, Nakelsky S, Hwang S, Mintz J, Altshuler LL. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:91–97.
   Google Scholar
• Kilbourne AM, Post EP, Bauer MS, Zeber JE, Copeland LA, Good CB, Pincus HA. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord. 2007;102:145–151.
   Google Scholar
• Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, Wohlheiter K, Mittal LP, Dixon LB. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis. 2006;194: 404–410.
   Google Scholar
• Dinesen H, Gram L, Andersen T, Dam M: Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70:65–69.
   Google Scholar
• Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002;43:514–517.
   Google Scholar
• Huang TL, Chen JF. Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005;80:55–59.
   Google Scholar
• Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975–981.
   Google Scholar
• Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, Kotler M, Weizman A. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neurophar-macol. 1999;22:98–101.
   Google Scholar
• Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156:1270–1272.
   Google Scholar
• Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry. 1999; 60:767–770.
   Google Scholar
• Guo JJ, Keck Jr PE, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry. 2006;67:1055–1061.
   Google Scholar
• Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W. Antip-sychotic exposure and type 2 diabetes among patients with schizophrenia: A matched case-control study of California Medic-aid claims. Pharmacoepidemiol Drug Saf. 2005;14: 417–425.
   Google Scholar
• Ollendorf DA, Joyce AT, Rucker M. Rate of new onset diabetes among patients treated with atypical or conventional antipsy-chotic medications for schizophrenia. MedGenMed. 2004;6:5.
   Google Scholar
• Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglyce-mia in patients treated with atypical antipsychotics. J Clin Psychiatry. 2005;66:1463–1467.
   Google Scholar
• Carlson C, Hornbuckle K, Delisle F, Kryzhanovskaya L, Breier A, Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol. 2006;16:366–375.
   Google Scholar
• Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19–28.
   Google Scholar
• Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsy-chotic-induced type 2 diabetes: Evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328–335.
   Google Scholar
• Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care. 2005;11:S235–241.
   Google Scholar
• Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255–262.
   Google Scholar
• Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperi-dol. Br J Psychiatry. 2005;187:537–543.
   Google Scholar
• Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 2006;8:232–241.
   Google Scholar
• Buckley PF, Miller DD, Singer B, Donenwirth K. The evolving clinical profile of atypical antipsychotic medications. Can J Psychiatry. 2001;46:285.
   Google Scholar
• SAS. Cary. SAS Institute Inc, 2003.
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
   Google Scholar
• Cornier MA, Tate CW, Grunwald GK, Bessesen DH. Relationship between waist circumference, body mass index, and medical care costs. Obes Res. 2002;10:1167–1172.
   Google Scholar
• Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res. 2003;11:1223–1231.
   Google Scholar
• Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444–2449.
   Google Scholar
• Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–1555.
   Google Scholar
• Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J Clin Psychiatry. 2006;67:1323–1326.
   Google Scholar
• Lambert TJ, Chapman LH. Diabetes, psychotic disorders, and antipsychotic therapy: A consensus statement. Med J Aust. 2004;181:544–548.
   Google Scholar
• De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second-generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006;21(Suppl 2):S11–15.
   Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.
   Google Scholar
• Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger Jr JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334–1349.
   Google Scholar